Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Australia shares fall as tech weighs, Melbourne extends lockdown

share with twitter share with LinkedIn share with facebook
09/06/2020 | 10:25pm EDT

* Tech rout continues, sub-index hits over 3-week low

* CSL signs agreements for potential COVID-19 vaccines

* Melbourne lockdown extended to late Sept.

Sept 7 (Reuters) - Australian shares fell nearly a percent on Monday, following the previous session's sell-off, after technology shares fell tracking their Wall Street peers on Friday and as Melbourne extended a coronavirus-led lockdown till late September.

The S&P/ASX 200 index fell 0.9% to 5,869.9 points by 0030 GMT on Monday, after it lost 3.1% in the previous session.

Technology stocks, the biggest percentage losers, fell 2.4% to hit their lowest level in more than three weeks.

Their losses follow the tech-heavy Nasdaq index's 1.3% fall on Friday after investors dumped heavyweight technology stocks due to concerns about high valuations.

Compounding worries of an economic recovery, the hot spot state of Victoria on Sunday extended a hard lockdown in Australia's second largest city due to a slower than hoped decline in its infection rate.

Victoria, which now accounts for about 75% of the country's total infections of 26,282, reported 63 new cases and five more deaths on Sunday.

Among tech firms, the biggest decliners were buy now pay later firm Afterpay Ltd down 4% and software firm Xero Ltd lost 2.3%.

Heavyweight financials, down 1%, weighed the most on the index, with top lenders Commonwealth Bank of Australia and Westpac Banking Corp falling 1% and 0.4%, respectively.

In a bright spot, CSL rose 2.8% after the heavyweight biotech firm said it signed an agreement with the Australian government to produce an AstraZeneca and Oxford University COVID-19 vaccine candidate.

CSL also signed an agreement with the government to supply 51 million doses of an alternative potential vaccine it is developing with the University of Queensland.

In New Zealand, the benchmark S&P/NZX 50 index swung between gains and losses. It was down 0.1% by 0049 GMT, with financials dragging the index.

(Reporting by Sameer Manekar in Bengaluru; Editing by Amy Caren Daniel)

Stocks mentioned in the article
ChangeLast1st jan.
AFTERPAY LIMITED 1.06% 102.13 End-of-day quote.248.80%
ASTRAZENECA PLC -0.15% 7943 Delayed Quote.4.42%
COMMONWEALTH BANK OF AUSTRALIA 0.82% 69.9 End-of-day quote.-12.52%
CSL LIMITED -0.51% 294.82 End-of-day quote.6.91%
NASDAQ COMP. 0.37% 11548.281629 Delayed Quote.28.71%
S&P/ASX 200 -0.11% 6167 Real-time Quote.-7.74%
WESTPAC BANKING CORPORATION 0.97% 18.78 End-of-day quote.-22.49%
XERO LIMITED -1.15% 114.01 End-of-day quote.42.51%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
10/24AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
10/24ASTRAZENECA : says its Oxford vaccine deal allows it to add up to 20% of manufac..
10/23NEWS HIGHLIGHTS : Top Company News of the Day
10/23NEWS HIGHLIGHTS : Top Company News of the Day
10/23Health Care Up After Final Presidential Debate -- Health Care Roundup
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
10/23ASTRAZENECA : Says FDA Authorises Restart Of COVID-19 Vaccine Trial in U.S.
10/23NEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (USD)
Sales 2020 26 703 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 178 M - -
P/E ratio 2020 47,1x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,58x
EV / Sales 2021 4,86x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,27 $
Last Close Price 103,58 $
Spread / Highest target 50,1%
Spread / Average Target 14,2%
Spread / Lowest Target -36,3%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999